SCHEDULE: RA Capital Adjusts VOR Biopharma Stake
Schedule 13D Amendment
RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of VOR Biopharma Inc. common stock to 19.9%.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed Amendment No. 15 to their Schedule 13D.
- This filing amends and supplements their original Schedule 13D, originally filed on February 19, 2021, with multiple previous amendments.
- The Reporting Persons' beneficial ownership of VOR Biopharma Inc. common stock has been adjusted.
- As of March 30, 2026, the total shares of common stock outstanding was 54,185,582.
- The Reporting Persons' beneficial ownership is now reported as 12,554,642 shares, representing 19.9% of the outstanding common stock.
- This percentage is based on the outstanding shares and includes shares held directly, underlying warrants, and stock options exercisable within 60 days.
- The filing details specific holdings including 3,935,608 shares of common stock directly held by the Fund, common stock warrants for up to 1,056,072 shares, and pre-funded warrants for up to 10,000,000 shares.
- Beneficial ownership also includes shares underlying vested stock options held by Joshua Resnick and Andrew Levin.
- The Fund is currently prohibited from exercising Common Stock Warrants due to a beneficial ownership blocker that limits ownership to 9.99%.
- The Fund is also restricted from exercising Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership exceeding 12,554,642 shares due to a blocker provision.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports changes in beneficial ownership and does not contain operational or financial performance updates.
Negatives
- The Fund is currently prohibited from exercising Common Stock Warrants due to a beneficial ownership blocker that limits ownership to 9.99% of outstanding shares.
- The Fund is also restricted from exercising Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership exceeding 12,554,642 shares due to a blocker provision.
Future Outlook
The filing does not contain specific forward-looking statements or guidance from the company. It primarily details changes in beneficial ownership and holdings of securities by RA Capital Management and its affiliates.
Industry Context
StockSavvy.ai notes that this filing represents a routine amendment to a Schedule 13D, indicating a significant investor, RA Capital Management, is adjusting its holdings or reporting changes in its beneficial ownership of VOR Biopharma Inc. Such filings are common in the biotechnology and pharmaceutical sectors where investment funds often take substantial stakes.
Stakeholder Impact
- Shareholders: The adjustment in RA Capital's stake may influence market perception and trading dynamics, though the filing itself does not indicate a change in strategic intent beyond ownership levels.
Key Dates
| Date | Description |
|---|---|
| 2021-02-19 | Original Schedule 13D filing date. |
| 2022-11-14 | Date of a previous amendment to Schedule 13D. |
| 2022-12-09 | Date of a previous amendment to Schedule 13D. |
| 2023-08-11 | Date of a previous amendment to Schedule 13D. |
| 2024-12-30 | Date of a previous amendment to Schedule 13D. |
| 2025-06-27 | Date of a previous amendment to Schedule 13D, including Exhibit 99.1 Joint Filing Agreement. |
| 2025-09-19 | Date of a previous amendment to Schedule 13D. |
| 2025-10-20 | Date of a previous amendment to Schedule 13D. |
| 2025-10-27 | Date of a previous amendment to Schedule 13D. |
| 2025-10-30 | Date of a previous amendment to Schedule 13D. |
| 2025-11-14 | Date of a previous amendment to Schedule 13D. |
| 2025-12-18 | Date of a previous amendment to Schedule 13D. |
| 2026-03-16 | Date of a previous amendment to Schedule 13D. |
| 2026-04-01 | Date of a previous amendment to Schedule 13D. |
| 2026-04-07 | Date as of which information was presented in the most recent prior amendment. |
| 2026-04-08 | Date of open market sale transactions by the Fund. |
| 2026-04-09 | Date of an open market sale transaction by the Fund. |
| 2026-04-10 | Date of an open market sale transaction by the Fund and the filing date of this Amendment No. 15. |
| 2026-03-30 | Date as of which shares of common stock outstanding were reported. |
| 2026-03-27 | Date of Issuer's Current Report on Form 8-K reporting shares outstanding. |
Keywords
Schedule 13D, RA Capital Management, VOR Biopharma, Beneficial Ownership, Common Stock, Warrants, Stock Options, SEC Filing, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.